Therapeutic antitumor efficacy of B cells loaded with tumor-derived autophagasomes vaccine (DRibbles)

Journal of Immunotherapy

Volumn 37, Issue 8, 2014, Pages 383-393

  Ren, Hongyan ^a,b   Zhao, Simin ^a   Li, Weixia ^a   Dong, Huixia ^a   Zhou, Meng ^a   Cao, Meng ^a   Hu, Hong Ming ^b,c   Wang, Li Xin ^a,b  

^a MEDICAL SCHOOL OF SOUTHEAST UNIVERSITY   (China)

^b Nanjing Second Hospital   (China)

^c PROVIDENCE PORTLAND MEDICAL CENTER   (United States)

Author keywords

Antigen cross presentation; Antitumor immunity; B cells; DRiPs containing blebs (DRibbles)

Indexed keywords

ANTIBODY; CANCER VACCINE; CD40 ANTIBODY; CD40 ANTIGEN; CPG OLIGODEOXYNUCLEOTIDE; DEFECTIVE RIBOSOMAL PRODUCTS CONTAINING AUTOPHAGOSOME RICH BLEBS VACCINE; GAMMA INTERFERON; TOLL LIKE RECEPTOR 9; TUMOR ANTIGEN; UNCLASSIFIED DRUG; OLIGODEOXYRIBONUCLEOTIDE;

ADOPTIVE TRANSFER; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ANTIBODY PRODUCTION; ANTIGEN PRESENTING CELL; ANTINEOPLASTIC ACTIVITY; ARTICLE; AUTOPHAGOSOME; B LYMPHOCYTE; CANCER IMMUNIZATION; CANCER INHIBITION; CANCER SURVIVAL; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CONTROLLED STUDY; CROSS PRESENTATION; CYTOKINE PRODUCTION; DENDRITIC CELL; DRUG EFFICACY; FEMALE; HUMORAL IMMUNITY; LIVER CELL CARCINOMA; LYMPHOCYTE TRANSFER; MOUSE; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; TUMOR REGRESSION; ADOPTIVE IMMUNOTHERAPY; ANIMAL; AUTOPHAGY; BAGG ALBINO MOUSE; C57BL MOUSE; HUMAN; IMMUNIZATION; IMMUNOLOGY; LYMPHOCYTE ACTIVATION; LYMPHOMA; METABOLISM; PHAGOSOME; PROCEDURES; TRANSGENIC MOUSE; TRANSPLANTATION; TUMOR VOLUME;

ADOPTIVE TRANSFER; ANIMALS; ANTIGENS, CD40; ANTIGENS, NEOPLASM; AUTOPHAGY; B-LYMPHOCYTES; CANCER VACCINES; CROSS-PRIMING; FEMALE; HUMANS; IMMUNIZATION, SECONDARY; IMMUNOTHERAPY, ADOPTIVE; INTERFERON-GAMMA; LYMPHOCYTE ACTIVATION; LYMPHOMA; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; MICE, TRANSGENIC; OLIGODEOXYRIBONUCLEOTIDES; PHAGOSOMES; T-LYMPHOCYTES; TUMOR BURDEN;

EID: 84925707756     PISSN: 15249557     EISSN: 15374513     Source Type: Journal    
DOI: 10.1097/CJI.0000000000000051     Document Type: Article

References (39)

1. Abeliovich H, Dunn WAJ, Kim J, et al. Dissection of autophagosome biogenesis into distinct nucleation and expansion steps. J Cell Biol. 2000; 151: 1025-1034.
2. Li YH, Wang LX, Pang P, et al. Cross presentation of tumor associated antigens through tumor-derived autophagosomes. Autophagy. 2009; 5: 576-577.
3. Li YH, Wang LX, Yang G, et al. Efficient cross-presentation depends on autophagy in tumor cells. Cancer Res. 2008; 68: 6889-6895.
4. Li YH, Wang LX, Pang P, et al. Tumor-derived autophago-some vaccine: mechanism of cross-presentation and therapeutic efficacy. Clin Cancer Res. 2011; 17: 1-11.
5. Hsu FJ, Benike C, Fagnoni F, et al. Vaccination of patients with B-cell lymphoma using autologous anti-gen-pulsed dendritic cells. Nat Med. 1996; 2: 52-58.
6. Nestle FO, Alijagic S, Gilliet M, et al. Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nat Med. 1998; 4: 328-332.
7. Lopez JA, Bioley G, Turtle CJ, et al. Single step enrichment of blood dendritic cells by positive immunoselection. J Immunol Methods. 2003; 274: 47-61.
8. Schultze JL, Michalak S, Seamon MJ, et al. CD40-activated human B-cells: an alternative source of highly efficient antigen presenting cells to generate autologous antigen-specific T cells for adoptive immunotherapy. J Clin Invest. 1997; 100: 2757-2765.
9. Kondo E, Gryschok L, Klein-Gonzalez N, et al. CD40-activated B-cells can be generated in high number and purity in cancer patients: analysis of immunogenicity and homing potential. Clin Exp Immunol. 2009; 155: 249-256.
10. von Bergwelt-Baildon M, Shimabukuro-Vornhagen A, Popov A, et al. CD40-activated B-cells express full lymph node homing triad and induce T-cell chemotaxis: potential as cellular adjuvants. Blood. 2006; 107: 2786-2789.
11. Penafuerte C, Ng S, Bautista-Lopez N, et al. B effector cells activated by a chimeric protein consisting of IL-2 and the ectodomain of TGF-β receptor II induce potent antitumor immunity. Cancer Res. 2012; 72: 1210-1220.
12. Guo S, Xu J, Denning W, et al. Induction of protective cytotoxic T cell responses by a B cell-based cellular vaccine requires stable expression of antigen. Gene Ther. 2009; 16: 1300-1313.
13. Candolfi M, Curtin JF, Yagiz K, et al. B-cells are critical to T-cell-mediated antitumor immunity induced by a combined immune-stimulatory conditionally cytotoxic therapy for glio-blastoma. Neoplasia. 2011; 13: 947-960.
14. Li W, Zhou M, Ren H, et al. Tumor-derived autophagosomes (DRibbles) induce B cell activation in a TLR2-MyD88 dependent manner. PLoS One. 2013; 8:e53564.
15. De Wit J, Souwer Y, Jorritsma T, et al. Antigen-specific B cells reactivate an effective cytotoxic T cell response against phagocytosed Salmonella through cross-presentation. PLoS One. 2010; 5:e13016.
16. Brayer J, Cheng F, Wang H, et al. Enhanced CD8 T cell cross-presentation by macrophages with targeted disruption of STAT3. Immunol Lett. 2010; 131: 126-130.
17. Jensen SM, Maston LD, Gough MJ, et al. Signaling through OX40 enhances antitumor immunity. Semin Oncol. 2010; 37: 524-532.
18. Su S, Zhou H, Xue M, et al. Anti-tumor efficacy of a hepatocellular carcinoma vaccine based on dendritic cells combined with tumor-derived autophagosomes in murine models. Asian Pac J Cancer Prev. 2013; 14: 3109-3116.
19. Wagner M, Poeck H, Jahrsdoerfer B, et al. IL-12p70-dependent Th1 induction by human B-cells requires combined activation with CD40 ligand and CpG DNA. J Immunol. 2004; 172: 954-963.
20. Shirota H, Sano K, Hirasawa N, et al. B-cells capturing antigen conjugated with CpGoligodeoxy nucleotides induce Th1 cells by elaborating IL-12. J Immunol. 2002; 169: 787-794.
21. Twitty CG, Jensen SM, Hu HM, et al. Tumor-derived autophagosome vaccine: induction of cross-protective immune responses against short-lived proteins through a p62-dependent mechanism. Clin Cancer Res. 2011; 17: 6467-6481.
22. Wiemann B, Starnes CO. Coley's toxins, tumor necrosis factor and cancer research: a historical perspective. Pharmacol Ther. 1994; 64: 529-564.
23. Murray JL, Gillogly ME, Przepiorka D, et al. Toxicity, immunogenicity, and induction of E75-specifictumor-lytic CTLs by HER-2 peptide E75 (369-377) combined with granulocyte macrophage colony-stimulating factor in HLA-A2+ patients with metastatic breast and ovarian cancer. Clin Cancer Res. 2002; 8: 3407-3418.
24. Avigan D, Vasir B, Gong J, et al. Fusion cell vaccination of patients with metastatic breast and renal cancer induces immunological and clinical responses. Clin Cancer Res. 2004; 10: 4699-4708.
25. Curigliano G, Spitaleri G, Dettori M, et al. Vaccine immunotherapy in breast cancer treatment: promising, but still early. Expert Rev Anticancer Ther. 2007; 7: 1225-1241.
26. Ellerman JE, Brown CK, de Vera M, et al. Masquerader: high mobility group box-1 and cancer. Clin Cancer Res. 2007; 13: 2836-2848.
27. Wang H, Bloom O, Zhang M, et al. HMG1 as a late mediator of endotoxin lethality in mice. Science. 1999; 285: 248-251.
28. Tang D, Kang R, Livesey KM, et al. Endogenous HMGB1 regulates autophagy. J Cell Biol. 2010; 190: 881-892.
29. Skinner M. Autophagy: in the hands of HMGB1. Nat Rev Mol Cell Biol. 2010; 11: 756-757.
30. Kang R, Livesey KM, Zeh HJ, et al. HMGB1: a novel Beclin 1-binding protein active in autophagy. Autophagy. 2010; 6: 1209-1211.
31. Lanzavecchia A. Antigen-specific interaction between T and B-cells. Nature. 1985; 314: 537-539.
32. Rock KL, Benacerraf B, Abbas AK. Antigen presentation by hapten-specific B lymphocytes. I. Role of surface immunoglobulin receptors. J Exp Med. 1984; 160: 1102-1113.
33. Ke Y, Kapp JA. Exogenous antigens gain access to the major histocompatibility complex class I processing pathway in B-cells by receptor-mediated uptake. J Exp Med. 1996; 184: 1179-1184.
34. Barnaba V, Franco A, Alberti A, et al. Selective killing of hepatitis B envelope antigen-specific B-cells by class I-restricted, exogenous antigen-specific T lymphocytes. Nature. 1990; 345: 258-260.
35. de Wit J, Souwer Y, Jorritsma T, et al. Antigen-specific B-cells reactivate an effective cytotoxic T cell response against phagocytosed Salmonella through cross-presentation. PLoS One. 2010; 5:e13016.
36. Grivel JC, Crook K, Leserman L. Endocytosis and presentation of liposome-associated antigens by B-cells. Immunomethods. 1994; 4: 223-228.
37. Vidard L, Kovacsovics-Bankowski M, Kraeft SK, et al. Analysis of MHC class II presentation of particulate antigens of B lymphocytes. J Immunol. 1996; 156: 2809-2818.
38. Lapointe R, Bellemare-Pelletier A, Housseau F, et al. CD40-stimulated B lymphocytes pulsed with tumor antigens are effective antigen-presenting cells that can generate specific T cells. Cancer Res. 2003; 63: 2836-2843.
39. Ahmadi T, Flies A, Efebera Y, et al. CD40 Ligand-activated, antigen-specific B-cells are comparable to mature dendritic cells in presenting protein antigens and major histocompatibility complex class I- and class II-binding peptides. Immunology. 2008; 124: 129-140.